American Academy of Dermatology Meeting
American Academy of Dermatology Meeting
March 08, 2017
4 min watch
Save

VIDEO: Long-term Dupixent plus topical corticosteroid treatment effective for AD

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

ORLANDO, Fla. —In a video perspective from the American Academy of Dermatology Annual Meeting, Andrew Blauvelt, MD, MBA, discusses his late-breaking research presentation on Dupixent with concomitant topical corticosteroids to treat moderate-to-severe atopic dermatitis.

Blauvelt, president of Oregon Medical Research Center, Portland, found that long-term treatment with Dupixent (dupilumab, Regeneron and Sanofi) plus topical corticosteroids improved atopic dermatitis signs and symptoms, including pruritus, with acceptable safety for up to 1 year when compared with topical corticosteroid treatment alone.